BACKGROUND: It has been proposed that laparoscopic adjustable gastric banding (LAGB) procedure might play a role in modulation of fundic ghrelin production. To test this hypothesis, we examined plasma and tissue concentrations of acylated ghrelin in morbidly obese patients before and 6 months after LAGB. Baseline levels of acylated ghrelin in morbidly obese patients were also compared with those in age-matched, healthy, non-obese controls. METHODS: We studied 21 patients who had been operated on for morbid obesity (M/F = 9/12, BMI = 49.3 ± 5.3 kg/m(2)) and 16 healthy, non-obese persons (M/F = 7/9, BMI = 23.0 ± 1.7 kg/m(2)). Fasting blood samples were collected once from the non-obese controls as well as the morbidly obese patients before and 6 months after the LAGB. The morbidly obese patients and their respective controls underwent gastroscopy for fundic biopsy. The plasma and fundic acylated ghrelin levels were evaluated in these groups by enzyme-linked immunosorbent assay. RESULTS: The plasma and fundic acylated ghrelin concentrations were significantly lower in obese patients than in non-obese controls (2.8 ± 1.0 ng/ml, 727 ± 171.7 ng/g tissue, respectively; p = 0.000). These parameters were significantly increased in morbidly obese patients 6 months after LAGB (4.1 ± 1.2 ng/ml and p = 0.001; 999 ± 292.1 ng/g tissue and p = 0.003, respectively). CONCLUSIONS: We showed that fundic production of acylated ghrelin was significantly increased in morbidly obese patients 6 months after LAGB. Moreover, the weight loss after LAGB occurred in spite of the significant increase in the plasma and fundic acylated ghrelin levels. The potential role of ghrelin as being responsible for the weight loss after bariatric surgery needs to be elucidated in further studies.
BACKGROUND: It has been proposed that laparoscopic adjustable gastric banding (LAGB) procedure might play a role in modulation of fundic ghrelin production. To test this hypothesis, we examined plasma and tissue concentrations of acylated ghrelin in morbidly obesepatients before and 6 months after LAGB. Baseline levels of acylated ghrelin in morbidly obesepatients were also compared with those in age-matched, healthy, non-obese controls. METHODS: We studied 21 patients who had been operated on for morbid obesity (M/F = 9/12, BMI = 49.3 ± 5.3 kg/m(2)) and 16 healthy, non-obesepersons (M/F = 7/9, BMI = 23.0 ± 1.7 kg/m(2)). Fasting blood samples were collected once from the non-obese controls as well as the morbidly obesepatients before and 6 months after the LAGB. The morbidly obesepatients and their respective controls underwent gastroscopy for fundic biopsy. The plasma and fundic acylated ghrelin levels were evaluated in these groups by enzyme-linked immunosorbent assay. RESULTS: The plasma and fundic acylated ghrelin concentrations were significantly lower in obesepatients than in non-obese controls (2.8 ± 1.0 ng/ml, 727 ± 171.7 ng/g tissue, respectively; p = 0.000). These parameters were significantly increased in morbidly obesepatients 6 months after LAGB (4.1 ± 1.2 ng/ml and p = 0.001; 999 ± 292.1 ng/g tissue and p = 0.003, respectively). CONCLUSIONS: We showed that fundic production of acylated ghrelin was significantly increased in morbidly obesepatients 6 months after LAGB. Moreover, the weight loss after LAGB occurred in spite of the significant increase in the plasma and fundic acylated ghrelin levels. The potential role of ghrelin as being responsible for the weight loss after bariatric surgery needs to be elucidated in further studies.
Authors: Gema Frühbeck; Alberto Diez-Caballero; M Jesús Gil; Inés Montero; Javier Gómez-Ambrosi; Javier Salvador; Javier A Cienfuegos Journal: Obes Surg Date: 2004-05 Impact factor: 4.129
Authors: S Marandi; N De Keyser; A Saliez; A S Maernoudt; E M Sokal; C Stilmant; M H Rider; J P Buts Journal: Am J Physiol Gastrointest Liver Physiol Date: 2001-02 Impact factor: 4.052
Authors: A Rodríguez; J Gómez-Ambrosi; V Catalán; M J Gil; S Becerril; N Sáinz; C Silva; J Salvador; I Colina; G Frühbeck Journal: Int J Obes (Lond) Date: 2009-02-24 Impact factor: 5.095
Authors: Bruno Geloneze; Marcos A Tambascia; Victor F Pilla; Sylka R Geloneze; Enrico M Repetto; José C Pareja Journal: Obes Surg Date: 2003-02 Impact factor: 4.129
Authors: Allison M Barrett; Kim T Vu; Kulmeet K Sandhu; Edward H Phillips; Scott A Cunneen; Miguel A Burch Journal: J Gastrointest Surg Date: 2014-08-14 Impact factor: 3.452